Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Anti-SARS-CoV-2 vaccines are being developed at an unprecedented pace, but what will the final vaccine or vaccines look like at approval and beyond? We asked six experts in vaccine development for their thoughts.
Glenda Gray is CEO of the South African Medical Research Council and the chair of the research committee on COVID-19 in South Africa. Julie Gerberding is Chief Patient Officer at Merck, former director of the US Centers for Disease Control and Prevention, and an associate adjunct professor of medicine (infectious diseases) at the University of California, San Francisco. Yoshi Kawaoka researches influenza and vaccine development and is a professor in the University of Wisconsin–Madison School of Veterinary Medicine. Rino Rappuoli is Chief Scientist and Head of External Research and Development at GlaxoSmithKline Vaccines. Hanneke Schuitemaker is VP Global Head Viral Vaccines Discovery and Translational Medicine at Johnson&Johnson. Lynda Stuart leads the vaccination team at the Bill & Melinda Gates Foundation.